Search results
The True Obesity Paradox: Obese and Malnourished?
Added:
1 year ago
Original Research
Targeting Obesity for Heart Failure
Added:
3 months ago
Review Article
Added:
1 year ago
How should obesity be redefined to establish objective criteria for improved disease diagnosis?In this short interview, Dr Robert Eckel (University of Colorado Anschutz Medical Campus, Aurora, US) discusses the recently published article, "Definition and diagnostic criteria of clinical obesity" based on the Lancet Diabetes and Endocrinology Commission's new consensus redefining obesity. The…
View more
Start date:
Jun 17, 2026
End date:
Jun 17, 2026
New Horizons in Obesity Management is a free-to-access, one-day virtual educational event on 17 June 2026.The event examines obesity as a central driver of cardio-renal-metabolic disease and a core contributor to multimorbidity across organ systems, and explores modern obesity pharmacotherapy as a potential disease-modifying intervention. New for 2026, the programme introduces three track-based…
View more
Added:
10 months ago
ERA 2025 - Dr Ruben Nogueiras (University of Santiago de Compostela, Santiago, ES) joins us to discuss upcoming treatments that will soon be approved for the treatment of obesity, including dual agonists that will also target type two diabetes. As well as exploring the evolution of our understanding and classification of obesity, Dr Nogueiras shares his view of obesity a multifactorial disease…
View more
Added:
1 year ago
In the first session of Advancements in Obesity Management (AOM) 2024, the panel introduce a patient living with obesity, including current diagnosis and cardiovascular complications of the disease. Furthermore, the emerging data leading to a revolution in the treatment of obesity is discussed.
View more
Added:
6 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Advancements in Obesity Management
Video Series
Added:
1 year ago
In the second session of Advancements in Obesity Management (AOM) 2024, the panel delve into treatment of specific CV diseases in patients living with obesity. Key co-morbidities discussed includediabetes, hypertension, dyslipidemia and thrombosis.
View more
Obesity and CKD: The Dual Epidemic in Cardiovascular Health
Added:
6 months ago
Review Article